Resolution No. 316 (Late A from Texas) - Support and Placement and Coverage of Long-Acting Reversible Contraceptives (LARC) for All Women as Contraceptive Devices and for Regulation of Dysfunctional Uterine Bleeding

Action Taken by the 2015 Congress of Delegates: Adopted


Resolution No. 316 (Late A)

Support and Placement and Coverage of Long-Acting Reversible Contraceptives (LARC) for All Women as Contraceptive Devices and for Regulation of Dysfunctional Uterine Bleeding

Introduced by the Texas Chapter

Referred to the Reference Committee on Practice Enhancement

WHEREAS, Birth intervals less than 18 months are associated with poor perinatal outcomes including preterm birth and low birth weight, and

WHEREAS, women who used Long-Acting Reversible Contraceptives (LARC) methods have a many-fold increased likelihood of achieving optimal birth interval compared women using other methods, and
WHEREAS, the ability to control the timing of her pregnancies is crucial to a woman’s socioeconomic advancement as it affects her education, employment, mental health, and ability to care for existing children, and

WHEREAS, currently the most significant barriers to providing LARC are related to billing and payment from Medicaid and private insurers, and

WHEREAS, evidence supports LARC as a well substantiated treatment option for dysfunctional uterine bleeding (reference ObGyn 2013, March 121 (3) 634-43, Nonsurgical Management of Heavy Menstrual Bleeding: a systematic review), and

WHEREAS, in a private practice and training environment, payment for LARC is often below the cost of obtaining the device or does not adequately pay for placement of the device as it is bundled with the purchase of the device, and

WHEREAS, the American Academy of Family Physicians has supported resolution to reduce barriers to LARC in the past, now, therefore, be it

RESOLVED. That the American Academy of Family Physicians support a policy of 36 adequate payment for Long-Acting Reversible Contraceptives (LARC) for all women, both 37 as a contraceptive option and as a treatment for dysfunctional bleeding.

(Received 9/28/15)